A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
Getting to the Moon was the first chapter. Interlune and Astrolab are working on how to operate there.
Updated
April 1, 2026 8:56 AM
Apollo 17 Astronaut's Snapshot of Taurus-Littrow Valley. PHOTO: UNSPLASH
As plans for a long-term human presence on the Moon pick up pace, the focus is shifting from landing there to working there. It is one thing to reach the surface. It is another to build roads, prepare sites and extract materials in a way that can support real activity.
That is where Interlune and Astrolab come in. Interlune is a space resources company. Astrolab builds planetary rovers. The two are now working together to mount Interlune’s lunar digging system onto Astrolab’s Flexible Logistics and Exploration (FLEX) rover. They have completed a concept study and are planning hardware testing in Houston.
The aim is straightforward: combine a rover that can move reliably across the Moon with equipment that can dig, collect and handle lunar soil. Interlune is focused on harvesting natural resources from the Moon, starting with helium-3. To do that at scale, the system cannot sit in one place. It has to move across the surface, handle dust and operate in harsh conditions. "Reliable, autonomous mobility is crucial to the Interlune harvesting system and broader lunar infrastructure development", said Rob Meyerson, co-founder and CEO of Interlune. "Astrolab's FLEX is the right vehicle for the job".
By fitting its digging and collection hardware onto FLEX, Interlune is working toward a mobile system that can gather large amounts of lunar soil and support future construction needs. Beyond helium-3, the same setup could help prepare base sites, level ground, build protective barriers and lay the groundwork for other structures. In simple terms, it is about turning a rover into a working machine for the Moon.
The partnership also connects to Interlune’s work with Vermeer Corporation to develop equipment for continuous, high-volume digging adapted to lunar conditions. Taken together, the goal is to build systems that can support both commercial and government missions — whether that means resource extraction or preparing land for future bases.
For Astrolab, the collaboration strengthens the role of FLEX as more than just a transport vehicle.
"Working with Interlune further differentiates FLEX as the rover of choice for commercial and government Moon missions", said Jaret Matthews, Astrolab founder and CEO. "Interlune's expertise in developing and testing highly specialized regolith simulant will further enhance FLEX's ability to mitigate dust and operate in extreme environments".
Testing will be centered in Houston, which is becoming an important hub for commercial space development. Astrolab was the first company to lease space at the Texas A&M University Space Institute, currently under construction at NASA’s Johnson Space Center. Interlune operates the Houston-based Interlune Research Lab, where it creates and tests simulated versions of lunar soil.
That detail matters. Moon dust is fine, abrasive and difficult to manage. Before any hardware flies, it needs to prove it can survive and function in those conditions. By testing their systems in realistic soil simulants, the companies can refine how the rover moves and how the digging system performs.
The Houston lab is partially funded by the Texas Space Commission, reflecting the growing role of regional space initiatives in supporting private companies building beyond Earth. Overall, the collaboration is not about grand promises. It is about integrating hardware, running real tests and taking practical steps toward operating on the Moon.